Abeer H A Mohamed Ahmed

Abeer H A Mohamed Ahmed

Auto-generated profile, based on publicly available information

Abeer H A Mohamed Ahmed

UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2017 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
SASahar Awwad
Sahar Awwad
AAAbeer H A Mohamed Ahmed
Abeer H A Mohamed Ahmed
GSGarima Sharma
Garima Sharma
JHJacob S Heng
Jacob S Heng
PKPeng T Khaw
Peng T Khaw
ALAlastair Lockwood
Alastair Lockwood

1 July 2016 in Drug Discovery Today
Verified
Journal Article
Open access
AMAbeer H.A. Mohamed-Ahmed
Abeer H.A. Mohamed-Ahmed
JSJessica Soto
Jessica Soto
TETerry Ernest
Terry Ernest
Catherine TuleuCatherine Tuleu
Catherine Tuleu
Taste evaluation is a crucial factor for determining acceptance of medicines by patients. The human taste panel test is the main method used to establish the overall palatability and acceptability of a drug product to a patient towards the end of development. Non-human in vitro and in vivo taste-evaluation tools are very useful for pre-formulation, quality control and screening of formulations. These non-human taste assessment tools can be used to evaluate all aspects of taste quality. The focus of this review is bitterness because it is a key aspect of taste in association with the development of medicines. In this review, recent in vitro (analytical) and in vivo (non-human) tools are described for the assessment of the bitter taste of medicines. Their correlations with human taste data are critically discussed. The potential for their use in early screening of the taste of active pharmaceutical ingredients (APIs) to expedite paediatric formulation development is also considered.

1 December 2012 in Current Opinion in Infectious Diseases
Verified
Journal Article
Closed access
AMAbeer H.A. Mohamed-Ahmed
Abeer H.A. Mohamed-Ahmed
SBStephen Brocchini
Stephen Brocchini
SCSimon L. Croft
Simon L. Croft
Amphotericin B (AmpB) is considered the first-line treatment for visceral leishmaniasis in areas in which resistance to antimony is prevalent. This review describes recent advances in clinically available and novel drug delivery systems of AmpB to treat visceral leishmaniasis. Over the past two decades, lipid-based AmpB formulations developed to tackle the toxicity of AmpB have been used clinically for the treatment of visceral leishmaniasis. Liposomal AmpB (AmBisome) has been the most successful lipid formulation, and recent clinical studies on visceral leishmaniasis have shown the potential of single-dose AmBisome treatment as well as its use in short course combinations with other antileishmanial drugs. Current research is focussed on the development of more stable and affordable nonlipid formulations of AmpB. Although a diverse range of nonlipid-based AmpB formulations have been evaluated, none have yet reached the clinic. Liposomal AmpB (AmBisome) has become a standard treatment, by intravenous infusion, for visceral leishmaniasis and the basis for new short course treatments. There have been extensive efforts to develop new AmpB formulations on the basis of polymers, lipids or physical aggregates of AmpB to replace the costly lipid-based formulations. However, no nonlipid-based AmpB delivery systems have yet reached the clinic.

1 August 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MMMagdalena Münster
Magdalena Münster
AMAbeer H.A. Mohamed-Ahmed
Abeer H.A. Mohamed-Ahmed
LILaura I. Immohr
Laura I. Immohr
CSCorinna Schoch
Corinna Schoch
CSCarsten Schmidt
Carsten Schmidt
JBJörg Breitkreutz
Jörg Breitkreutz

1 January 2018 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
LCLaurence C Cheung
Laurence C Cheung
MNMinh Nguyen
Minh Nguyen
ETEdith Tang
Edith Tang
BUBritta Sylvia von Ungern-Sternberg
Britta Sylvia von Ungern-Sternberg
SSSam Salman
Sam Salman
Lee Yong LimLee Yong Lim
Lee Yong Lim

21 February 2017 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PDF file
AMAbeer H A Mohamed-Ahmed
Abeer H A Mohamed-Ahmed
MWMatthew Wilson
Matthew Wilson
MAMaedelyn Albuera
Maedelyn Albuera
TCTing Chen
Ting Chen
PMPhilippa Mills
Philippa Mills
CTCatherine Tuleu
Catherine Tuleu